Department of Internal Medicine, University Hospital Královské Vinohrady, 100 34 Prague, Czech Republic.
Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic.
Medicina (Kaunas). 2023 Apr 12;59(4):752. doi: 10.3390/medicina59040752.
: Recently, rapid progress has been made in the development of noninvasive methods for liver fibrosis assessment. The study aimed to assess the correlation between LSM and serum fibrosis markers to identify patients with advanced liver fibrosis in daily clinical practice. : Between 2017 and 2019, 89 patients with chronic liver disease of various etiology, 58 males and 31 females, were enrolled in the study and underwent ultrasound examination, vibration-controlled transient elastography (VCTE), AST to Platelet Ratio Index (APRI score), Fibrosis-4 (FIB-4) score, and enhanced liver fibrosis (ELF) test. : The diagnoses were as follows: NAFLD (30.3%), HCV (24.3%), HBV (13.1%), ALD (10.1%), other (7.8%). Their median age was 49 (21-79), and their median BMI was 27.5 (18.4-39.5). The median liver stiffness measurement (LSM) was 6.7 kPa (2.9-54.2 kPa), the median of the ELF test was 9.0 (7.3-12.6), and the median APRI was 0.40 (0.13-3.13). Advanced fibrosis assessed by LSM was present in 18/89 (20.2%) patients. The LSM values correlated with the ELF test results (r = 0.31, < 0.0001), with the APRI score (r = 0.23, < 0.0001), the age of the patients (r = 0.14, < 0.001), and with the FIB-4 values (r = 0.58, < 0.0001). The ELF test values correlated with the APRI score (r = 0.14, = 0.001), the age (r = 0.38, < 0.0001), and the FIB-4 (r = 0.34, < 0.0001). By determining the confidence intervals of the linear model, we proved that patients younger than 38.1 years have a 95% probability of absence of advanced liver fibrosis when assessed by VCTE. : We identified APRI and FIB-4 as simple tools for screening liver disease in primary care in an unselected population of patients. The results also showed that individuals younger than 38.1 years had a negligible risk of advanced liver fibrosis.
: 最近,非侵入性肝纤维化评估方法的发展取得了快速进展。本研究旨在评估 LSM 与血清纤维化标志物之间的相关性,以在日常临床实践中识别进展性肝纤维化患者。: 2017 年至 2019 年,共纳入 89 例不同病因的慢性肝病患者,男 58 例,女 31 例,行超声检查、振动控制瞬时弹性成像(VCTE)、天冬氨酸转氨酶与血小板比值指数(APRI 评分)、纤维化-4(FIB-4)评分和增强肝纤维化(ELF)检测。: 诊断为非酒精性脂肪性肝病(NAFLD,30.3%)、丙型肝炎病毒(HCV,24.3%)、乙型肝炎病毒(HBV,13.1%)、酒精性肝病(ALD,10.1%)和其他(7.8%)。中位年龄 49 岁(21-79 岁),中位 BMI 为 27.5kg/m²(18.4-39.5kg/m²)。中位肝硬度测量值(LSM)为 6.7kPa(2.9-54.2kPa),中位 ELF 检测值为 9.0(7.3-12.6),中位 APRI 为 0.40(0.13-3.13)。18/89(20.2%)例患者存在 LSM 评估的进展性肝纤维化。LSM 值与 ELF 检测结果(r=0.31,<0.0001)、APRI 评分(r=0.23,<0.0001)、患者年龄(r=0.14,<0.001)和 FIB-4 值(r=0.58,<0.0001)相关。ELF 检测值与 APRI 评分(r=0.14,=0.001)、年龄(r=0.38,<0.0001)和 FIB-4(r=0.34,<0.0001)相关。通过确定线性模型的置信区间,我们证明在 VCTE 评估中,年龄<38.1 岁的患者患有进展性肝纤维化的概率为 95%。: 我们确定 APRI 和 FIB-4 为初级保健中筛选未选择人群中肝病的简单工具。结果还表明,年龄<38.1 岁的个体患有进展性肝纤维化的风险可以忽略不计。